Literature DB >> 28474999

Cell division cycle 45 promotes papillary thyroid cancer progression via regulating cell cycle.

Jing Sun1, Run Shi2, Sha Zhao3, Xiaona Li4, Shan Lu5, Hemei Bu1, Xianghua Ma1.   

Abstract

Cell division cycle 45 was reported to be overexpressed in some cancer-derived cell lines and was predicted to be a candidate oncogene in cervical cancer. However, the clinical and biological significance of cell division cycle 45 in papillary thyroid cancer has never been investigated. We determined the expression level and clinical significance of cell division cycle 45 using The Cancer Genome Atlas, quantitative real-time polymerase chain reaction, and immunohistochemistry. A great upregulation of cell division cycle 45 was observed in papillary thyroid cancer tissues compared with adjacent normal tissues. Furthermore, overexpression of cell division cycle 45 positively correlates with more advanced clinical characteristics. Silence of cell division cycle 45 suppressed proliferation of papillary thyroid cancer cells via G1-phase arrest and inducing apoptosis. The oncogenic activity of cell division cycle 45 was also confirmed in vivo. In conclusion, cell division cycle 45 may serve as a novel biomarker and a potential therapeutic target for papillary thyroid cancer.

Entities:  

Keywords:  Papillary thyroid cancer; The Cancer Genome Atlas; cell cycle; proliferation

Mesh:

Substances:

Year:  2017        PMID: 28474999     DOI: 10.1177/1010428317705342

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  19 in total

1.  [Deguelin inhibits proliferation and regulates the expression of MCM3-CDC45 in MCF-7 and H1299 cells in vitro].

Authors:  Yu-Lin Fan; Rui-Jin Liu; Xiao-Yan Ding; Xin-Yi Shangguan; Xin-Rong Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-11-20

2.  Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.

Authors:  Elizabeth A Mazzio; Karam F A Soliman
Journal:  Cancer Genomics Proteomics       Date:  2018 Sep-Oct       Impact factor: 4.069

3.  High abundance of CDC45 inhibits cell proliferation through elevation of HSPA6.

Authors:  Yuanyuan Fu; Zhiyi Lv; Deqing Kong; Yuping Fan; Bo Dong
Journal:  Cell Prolif       Date:  2022-06-01       Impact factor: 8.755

4.  Identification of Hub Genes for Early Diagnosis and Predicting Prognosis in Colon Adenocarcinoma.

Authors:  Shuo Xu; Dingsheng Liu; Mingming Cui; Yao Zhang; Yu Zhang; Shiqi Guo; Hong Zhang
Journal:  Biomed Res Int       Date:  2022-06-21       Impact factor: 3.246

5.  Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer.

Authors:  Jinhui Liu; Jie Mei; Siyue Li; Zhipeng Wu; Yan Zhang
Journal:  Cancer Cell Int       Date:  2020-07-20       Impact factor: 5.722

6.  Identification of potential core genes and pathways predicting pathogenesis in head and neck squamous cell carcinoma.

Authors:  Mengmeng Wang; Bin Zhong; Man Li; Yanjuan Wang; Huaian Yang; Ke Du
Journal:  Biosci Rep       Date:  2021-05-28       Impact factor: 3.840

Review 7.  The Human Replicative Helicase, the CMG Complex, as a Target for Anti-cancer Therapy.

Authors:  Yeon-Soo Seo; Young-Hoon Kang
Journal:  Front Mol Biosci       Date:  2018-03-29

8.  KNK437 restricts the growth and metastasis of colorectal cancer via targeting DNAJA1/CDC45 axis.

Authors:  Shaoshan Yang; Xiaoli Ren; Yunshi Liang; Yongrong Yan; Yangshu Zhou; Jinlong Hu; Zhizhi Wang; Fuyao Song; Feifei Wang; Wangjun Liao; Wenting Liao; Yanqing Ding; Li Liang
Journal:  Oncogene       Date:  2019-09-02       Impact factor: 9.867

9.  MINA53 deficiency leads to glioblastoma cell apoptosis via inducing DNA replication stress and diminishing DNA damage response.

Authors:  Fan Xuan; Mengying Huang; Erhu Zhao; Hongjuan Cui
Journal:  Cell Death Dis       Date:  2018-10-17       Impact factor: 8.469

10.  Identification of genes associated with clinicopathological features of colorectal cancer.

Authors:  Xiaoting Wang; Shouzi Hu; Wenbin Ji; Yan Tang; Shulong Zhang
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.